Novo Nordisk lowered its sales forecast for obesity drug Wegovy, citing competition from compounded versions. Scott Olson/Getty Images hide caption toggle caption Scott Olson/Getty Images Novo Nordisk’s shares plunged more than 20% Tuesday, after the company cut the forecast for its flagship obesity drug. Before the markets opened, the company announced that sales of its obesity medicine, Wegovy, are expected …
Read More »Compounding Novo Nordisk slashes Wegovy sales forecasts, blames compounding. : Shots
